{"pmid":32449171,"title":"COVID-19: are neutralizing antibodies neutralizing enough?","text":["COVID-19: are neutralizing antibodies neutralizing enough?","Transfusion","Kadkhoda, Kamran","32449171"],"journal":"Transfusion","authors":["Kadkhoda, Kamran"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32449171","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/trf.15897","keywords":["covid-19","convalescent plasma","sars-cov-2","treatment"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667785213996957696,"score":9.490897,"similar":[{"pmid":32249063,"pmcid":"PMC7129017","title":"Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.","text":["Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.","Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.","Trends Immunol","Jiang, Shibo","Hillyer, Christopher","Du, Lanying","32249063"],"abstract":["Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs."],"journal":"Trends Immunol","authors":["Jiang, Shibo","Hillyer, Christopher","Du, Lanying"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32249063","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.it.2020.03.007","keywords":["mers-cov","sars-cov","sars-cov-2","human coronaviruses","neutralizing antibodies"],"link_erratum_in":"32362491","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490933346306,"score":87.299904},{"pmid":32346091,"pmcid":"PMC7186944","title":"Neutralizing antibody response in mild COVID-19.","text":["Neutralizing antibody response in mild COVID-19.","Nat Rev Immunol","van der Heide, Verena","32346091"],"journal":"Nat Rev Immunol","authors":["van der Heide, Verena"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32346091","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1038/s41577-020-0325-2","topics":["Diagnosis","Mechanism"],"weight":1,"_version_":1666138495385600001,"score":81.926796},{"pmid":32450171,"title":"Coronaviruses pandemics: Can neutralizing antibodies help?","text":["Coronaviruses pandemics: Can neutralizing antibodies help?","For the first time in Homo sapiens history, possibly, most of human activities is stopped by coronavirus disease 2019 (COVID-19). Nearly eight billion people of this world are facing a great challenge, maybe not \"to be or not to be\" yet, but unpredictable. What happens to other major pandemics in the past, and how human beings went through these hurdles? The human body is equipped with the immune system that can recognize, respond and fight against pathogens such as viruses. Following the innate response, immune system processes the adaptive response by which each pathogen is encoded and recorded in memory system. The humoral reaction containing cytokines and antibodies is expected to activate when the pathogens come back. Exploiting this nature of body protection, neutralizing antibodies have been investigated. Learning from past, in parallel to SARS-CoV-2, other coronaviruses SARS-CoV and MERS-CoV who caused previous pandemics, are recalled in this review. We here propose insights of origin and characteristics and perspective for the future of antibodies development.","Life Sci","Tong, Phuoc-Bao-Viet","Lin, Li-Yun","Tran, Tuan Hiep","32450171"],"abstract":["For the first time in Homo sapiens history, possibly, most of human activities is stopped by coronavirus disease 2019 (COVID-19). Nearly eight billion people of this world are facing a great challenge, maybe not \"to be or not to be\" yet, but unpredictable. What happens to other major pandemics in the past, and how human beings went through these hurdles? The human body is equipped with the immune system that can recognize, respond and fight against pathogens such as viruses. Following the innate response, immune system processes the adaptive response by which each pathogen is encoded and recorded in memory system. The humoral reaction containing cytokines and antibodies is expected to activate when the pathogens come back. Exploiting this nature of body protection, neutralizing antibodies have been investigated. Learning from past, in parallel to SARS-CoV-2, other coronaviruses SARS-CoV and MERS-CoV who caused previous pandemics, are recalled in this review. We here propose insights of origin and characteristics and perspective for the future of antibodies development."],"journal":"Life Sci","authors":["Tong, Phuoc-Bao-Viet","Lin, Li-Yun","Tran, Tuan Hiep"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32450171","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.lfs.2020.117836","keywords":["antibodies","covid-19","mers-cov","sars-cov","sars-cov-2"],"topics":["Mechanism"],"weight":1,"_version_":1667785214010589184,"score":81.50524},{"pmid":32454513,"title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection.","text":["Human neutralizing antibodies elicited by SARS-CoV-2 infection.","The emerging coronavirus SARS-CoV-2 pandemic presents a global health emergency in urgent need of interventions(1-3). SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor(2,4-6). Here, we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells of eight SARS-CoV-2 infected individuals. We identified antibodies with potent anti-SARS-CoV-2 neutralization activity that correlates with their competitive capacity with ACE2 for RBD binding. Surprisingly, neither the anti-SARS-CoV-2 antibodies nor the infected plasma cross-reacted with SARS-CoV or MERS-CoV RBDs, although substantial plasma cross-reactivity to their trimeric Spike proteins was found. Crystal structure analysis of RBD-bound antibody revealed steric hindrance that inhibits viral engagement with ACE2 and thereby blocks viral entry. These findings suggest that anti-RBD antibodies are viral species-specific inhibitors. The antibodies identified here may be candidates for the development of SARS-CoV-2 clinical interventions.","Nature","Ju, Bin","Zhang, Qi","Ge, Jiwan","Wang, Ruoke","Sun, Jing","Ge, Xiangyang","Yu, Jiazhen","Shan, Sisi","Zhou, Bing","Song, Shuo","Tang, Xian","Yu, Jinfang","Lan, Jun","Yuan, Jing","Wang, Haiyan","Zhao, Juanjuan","Zhang, Shuye","Wang, Youchun","Shi, Xuanling","Liu, Lei","Zhao, Jincun","Wang, Xinquan","Zhang, Zheng","Zhang, Linqi","32454513"],"abstract":["The emerging coronavirus SARS-CoV-2 pandemic presents a global health emergency in urgent need of interventions(1-3). SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor(2,4-6). Here, we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells of eight SARS-CoV-2 infected individuals. We identified antibodies with potent anti-SARS-CoV-2 neutralization activity that correlates with their competitive capacity with ACE2 for RBD binding. Surprisingly, neither the anti-SARS-CoV-2 antibodies nor the infected plasma cross-reacted with SARS-CoV or MERS-CoV RBDs, although substantial plasma cross-reactivity to their trimeric Spike proteins was found. Crystal structure analysis of RBD-bound antibody revealed steric hindrance that inhibits viral engagement with ACE2 and thereby blocks viral entry. These findings suggest that anti-RBD antibodies are viral species-specific inhibitors. The antibodies identified here may be candidates for the development of SARS-CoV-2 clinical interventions."],"journal":"Nature","authors":["Ju, Bin","Zhang, Qi","Ge, Jiwan","Wang, Ruoke","Sun, Jing","Ge, Xiangyang","Yu, Jiazhen","Shan, Sisi","Zhou, Bing","Song, Shuo","Tang, Xian","Yu, Jinfang","Lan, Jun","Yuan, Jing","Wang, Haiyan","Zhao, Juanjuan","Zhang, Shuye","Wang, Youchun","Shi, Xuanling","Liu, Lei","Zhao, Jincun","Wang, Xinquan","Zhang, Zheng","Zhang, Linqi"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454513","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1038/s41586-020-2380-z","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667881798493798400,"score":81.12189},{"pmid":32375025,"title":"Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.","text":["Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.","Coronaviruses make use of a large envelope protein called spike (S) to engage host cell receptors and catalyze membrane fusion. Because of the vital role that these S proteins play, they represent a vulnerable target for the development of therapeutics. Here, we describe the isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes. These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. Crystal structures of these VHHs bound to their respective viral targets reveal two distinct epitopes, but both VHHs interfere with receptor binding. We also show cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S and demonstrate that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion. These data provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful therapeutics during coronavirus outbreaks.","Cell","Wrapp, Daniel","De Vlieger, Dorien","Corbett, Kizzmekia S","Torres, Gretel M","Wang, Nianshuang","Van Breedam, Wander","Roose, Kenny","van Schie, Loes","Hoffmann, Markus","Pohlmann, Stefan","Graham, Barney S","Callewaert, Nico","Schepens, Bert","Saelens, Xavier","McLellan, Jason S","32375025"],"abstract":["Coronaviruses make use of a large envelope protein called spike (S) to engage host cell receptors and catalyze membrane fusion. Because of the vital role that these S proteins play, they represent a vulnerable target for the development of therapeutics. Here, we describe the isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes. These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. Crystal structures of these VHHs bound to their respective viral targets reveal two distinct epitopes, but both VHHs interfere with receptor binding. We also show cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S and demonstrate that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion. These data provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful therapeutics during coronavirus outbreaks."],"journal":"Cell","authors":["Wrapp, Daniel","De Vlieger, Dorien","Corbett, Kizzmekia S","Torres, Gretel M","Wang, Nianshuang","Van Breedam, Wander","Roose, Kenny","van Schie, Loes","Hoffmann, Markus","Pohlmann, Stefan","Graham, Barney S","Callewaert, Nico","Schepens, Bert","Saelens, Xavier","McLellan, Jason S"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32375025","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cell.2020.04.031","keywords":["covid-19","mers","sars","sars-cov-2","nanobody"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496443613185,"score":78.63748}]}